My takeaways are:
Overall they are progressing well (albeit slower than most would like) with continued pleasing results.
It should only be at least 9 months for the commencement of preclinical trials on the I-myc cancer program (2h-2017).
"Since the end of June, we’ve signed an additional 2 new non-disclosure agreements with international
pharmaceutical companies to discuss elements of Phylogica’s technology portfolio" Top secret discussions to continue.
"In coming months, we expect to have further information on some of our ongoing collaborations, including with Phoremost, the Dana Farber Institute in the US (researching our Phylomer inhibitors aimed at the STAT5 and YB1 oncology targets) and our Genentech collaboration on antimicrobials. I will give them until the end of the year.
If slow and steady was a signal to invest in a company then people would be jumped in droves...
It would appear their thoughts are finally moving towards commercialization:
"Business development and commercialisation advisors with extensive experience in the
pharmaceutical industry have been engaged to assist in maximising the potential of Phylogica’s
assets".
(20min delay)